CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization ...Middle East

SHANGHAI, June 20, 2026 /PRNewswire/ -- CureGene Pharmaceutical today announced that the first participant has been successfully dosed in the U.S. pivotal clinical trial of Evategrel (CG-0255), its proprietary new-generation best-in-class antiplatelet agent. This milestone marks a...

Hence then, the article about curegene achieves first participant dosed in u s pivotal trial for evategrel cg 0255 a best in class antiplatelet drug accelerating global commercialization was published today ( Sunday 21/06/2026 - 03:53 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization )

Also on site :

• Alix Earle Said She Wants to Date a Rock Star, and She May Have Gotten Her Wish
• The West is losing the diplomacy war and ASEAN is quietly winning it
• I Taste-Tested 10 Popular Electrolyte Powders—Here's the One I'd Buy Again